文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

雄激素抑制对男性COVID-19住院患者临床结局的影响:HITCH随机临床试验

Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2022-04-01
一句话结论在男性COVID-19住院患者中,地加瑞克单次240 mg皮下注射未能改善第15天复合终点(30.6% vs 26.5%,P=.67),该试验因无效提前终止。

HITCH是一项2期、安慰剂对照、双盲随机临床试验,在14家退伍军人事务部医院纳入不需要有创机械通气的男性COVID-19住院患者,按2:1随机接受地加瑞克(单次皮下240 mg)或生理盐水安慰剂,均联合标准治疗。计划中期分析后因无效终止,共96例可评估(地加瑞克62例、安慰剂34例)。主要复合终点(第15天死亡、仍需住院或需要有创机械通气)两组无显著差异(19例[30.6%] vs 9例[26.5%],P=.67),所有次要终点亦无差异。地加瑞克未减轻COVID-19严重程度。

要点

  • 地加瑞克组与安慰剂组主要复合终点(第15天死亡、仍需住院或需机械通气)无显著差异:19例(30.6%)vs 9例(26.5%),P=.67。
  • 住院死亡率两组无差异:地加瑞克组11例(17.7%)vs 安慰剂组6例(17.6%);全因死亡率11例(17.7%)vs 7例(20.6%)。
  • 所有次要终点(至临床改善时间、住院时长、机械通气时长、体温恢复正常时间、COVID-19最大严重程度、第30天复合终点)均无差异。
  • 不良事件总发生率两组无差异:13例(21.0%)vs 8例(23.5%);严重不良事件19例(30.6%)vs 13例(32.4%),无意外安全性问题。
  • 试验在计划中期分析后因无效终止,原计划198例,实际可评估96例(地加瑞克62例、安慰剂34例)。

适用人群与场景

  • 在14家退伍军人事务部医院住院的男性COVID-19患者,不需要有创机械通气。
  • 纳入时间为2020年7月22日至2021年4月8日。
  • 常见合并症包括高血压75例(78.1%)、糖尿病49例(51.0%)、心血管疾病27例(28.1%)、慢性阻塞性肺疾病15例(15.6%)、哮喘12例(12.5%)、COVID-19前即需补充氧气的慢性呼吸衰竭9例(9.4%)。

处置流程与药物剂量

  • 地加瑞克组:单次皮下注射地加瑞克240 mg,联合标准治疗。
  • 安慰剂组:单次皮下注射生理盐水安慰剂,联合标准治疗。
  • 标准治疗包括但不限于补充氧气、抗生素、血管升压药支持、腹膜透析或血液透析、静脉输液、瑞德西韦、恢复期血浆和地塞米松。

研究设计与关键结果

  • 研究类型:2期、安慰剂对照、双盲、随机临床试验;14家退伍军人事务部医院;计划纳入198例,因无效终止时96例可评估(地加瑞克组62例、安慰剂组34例)。
  • 中位(范围)年龄70.5(48-85)岁;按年龄、高血压病史和疾病严重程度分层后中央随机2:1分配。
  • 主要复合终点(随机后第15天死亡、仍需住院或需要有创机械通气):地加瑞克组19例(30.6%)vs 安慰剂组9例(26.5%),P=.67,无显著差异。
  • 住院死亡率:地加瑞克组11例(17.7%)vs 安慰剂组6例(17.6%);全因死亡率:11例(17.7%)vs 7例(20.6%),均无差异。
  • 所有次要终点(至临床改善时间、住院时长、机械通气时长、体温恢复正常时间、COVID-19最大严重程度、第30天复合终点)两组均无差异。
  • 不良事件总发生率:地加瑞克组13例(21.0%)vs 安慰剂组8例(23.5%);严重不良事件:19例(30.6%)vs 13例(32.4%);无意外安全性问题。

证据类型、等级与局限

  • 证据类型:2期随机、双盲、安慰剂对照临床试验。
  • 试验因无效在计划中期分析后终止,实际可评估96例,低于原计划198例。

对床旁实践的改变

  • 对于不需要有创机械通气的男性COVID-19住院患者,地加瑞克单次240 mg皮下注射未能改善第15天死亡、仍需住院或需机械通气的复合终点,也未改善任何次要终点,不改变现有标准治疗。
  • 地加瑞克组与安慰剂组不良事件和严重不良事件发生率无差异,无意外安全性问题。
  • 作者结论:在男性COVID-19住院患者中,与安慰剂联合常规治疗相比,雄激素抑制(地加瑞克)未能减轻COVID-19严重程度。

指南或共识出处

  • ClinicalTrials.gov注册号:NCT04397718。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: SARS-CoV-2 entry requires the TMPRSS2 cell surface protease. Antiandrogen therapies reduce expression of TMPRSS2.

OBJECTIVE: To determine if temporary androgen suppression induced by degarelix improves clinical outcomes of inpatients hospitalized with COVID-19.

DESIGN, SETTING, AND PARTICIPANTS: The Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH) phase 2, placebo-controlled, double-blind, randomized clinical trial compared efficacy of degarelix plus standard care vs placebo plus standard care on clinical outcomes in men hospitalized with COVID-19 but not requiring invasive mechanical ventilation. Inpatients were enrolled at 14 Department of Veterans Affairs hospitals from July 22, 2020, to April 8, 2021. Data were analyzed from August 9 to October 15, 2021.

INTERVENTIONS: Patients stratified by age, history of hypertension, and disease severity were centrally randomized 2:1 to degarelix, (1-time subcutaneous dose of 240 mg) or a saline placebo. Standard care included but was not limited to supplemental oxygen, antibiotics, vasopressor support, peritoneal dialysis or hemodialysis, intravenous fluids, remdesivir, convalescent plasma, and dexamethasone.

MAIN OUTCOMES AND MEASURES: The composite primary end point was mortality, ongoing need for hospitalization, or requirement for mechanical ventilation at day 15 after randomization. Secondary end points were time to clinical improvement, inpatient mortality, length of hospitalization, duration of mechanical ventilation, time to achieve a temperature within reference range, maximum severity of COVID-19, and the composite end point at 30 days.

RESULTS: The trial was stopped for futility after the planned interim analysis, at which time there were 96 evaluable patients, including 62 patients randomized to the degarelix group and 34 patients in the placebo group, out of 198 initially planned. The median (range) age was 70.5 (48-85) years. Common comorbidities included chronic obstructive pulmonary disorder (15 patients [15.6%]), hypertension (75 patients [78.1%]), cardiovascular disease (27 patients [28.1%]), asthma (12 patients [12.5%]), diabetes (49 patients [51.0%]), and chronic respiratory failure requiring supplemental oxygen at baseline prior to COVID-19 (9 patients [9.4%]). For the primary end point, there was no significant difference between the degarelix and placebo groups (19 patients [30.6%] vs 9 patients [26.5%]; P = .67). Similarly, no differences were observed between degarelix and placebo groups in any secondary end points, including inpatient mortality (11 patients [17.7%] vs 6 patients [17.6%]) or all-cause mortality (11 patients [17.7%] vs 7 patents [20.6%]). There were no differences between degarelix and placebo groups in the overall rates of adverse events (13 patients [21.0%] vs 8 patients [23.5%) and serious adverse events (19 patients [30.6%] vs 13 patients [32.4%]), nor unexpected safety concerns.

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of androgen suppression vs placebo and usual care for men hospitalized with COVID-19, degarelix did not result in amelioration of COVID-19 severity.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04397718.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Nickols NG, Mi Z, DeMatt E, et al. Effect of Androgen Suppression on Clinical Outcomes in Hospitalized Men With COVID-19: The HITCH Randomized Clinical Trial. JAMA Netw Open. 2022. PMID: 35438754. doi:10.1001/jamanetworkopen.2022.7852

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。